AZRX AzurRx BioPharma, Inc. Stock Quote

AZRX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.21	Insider Own	1.03%	Shs Outstand	74.44M	Perf Week	-5.08%
Market Cap	70.89M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	73.00M	Perf Month	20.59%
Income	-66.50M	PEG	-	EPS next Q	-0.07	Inst Own	4.10%	Short Float	3.28%	Perf Quarter	-43.65%
Sales	-	P/S	-	EPS this Y	-116.80%	Inst Trans	61.23%	Short Ratio	0.69	Perf Half Y	14.18%
Book/sh	0.46	P/B	1.89	EPS next Y	3.40%	ROA	-487.80%	Target Price	-	Perf Year	-6.48%
Cash/sh	0.15	P/C	5.91	EPS next 5Y	-	ROE	-	52W Range	0.65 - 2.63	Perf YTD	-10.54%
Dividend	-	P/FCF	-	EPS past 5Y	-19.00%	ROI	-	52W High	-67.28%	Beta	1.52
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	-	Gross Margin	-	52W Low	32.38%	ATR	0.06
Employees	12	Current Ratio	3.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.92	Volatility	4.87% 6.76%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	-392.90%	Profit Margin	-	Rel Volume	0.31	Prev Close	0.87
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	3.48M	Price	0.86
Recom	2.20	SMA20	0.97%	SMA50	0.46%	SMA200	-12.32%	Volume	772,321	Change	-0.83%

Jan-06-21

Downgrade

Dawson James

Buy → Neutral

Jun-11-19

Initiated

National Securities

Buy

Oct-17-18

Initiated

Oppenheimer

Outperform

Jul-24-17

Initiated

H.C. Wainwright

Buy

Jun-08-21 07:00AM	AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital GlobeNewswire
Jun-07-21 07:00AM	AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections GlobeNewswire +6.45%
Jun-04-21 02:01PM	UPDATE - FMW Media, Inc.s New to The Street TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET GlobeNewswire
01:02PM	FMW Media, Inc.s New to The Street TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET GlobeNewswire
May-19-21 07:30AM	AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26) GlobeNewswire
May-14-21 03:00PM	FMW Media, Inc.s New to The Street TV Announces 8 Interviews Being Broadcast on NEWSMAX TV, Sunday, May 16, 2021, Hour Slot 10-11AM ET. GlobeNewswire +8.35%
02:45PM	FMW Medias New To The Street Syndicated TV Show Features AzurRx BioPharma, Inc. GlobeNewswire
May-13-21 08:49AM	AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency Benzinga
07:00AM	AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
May-12-21 07:30AM	AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit) GlobeNewswire
May-11-21 08:30AM	AzurRx BioPharma to Present at the Emerging Growth Conference (May 12) GlobeNewswire
07:30AM	AzurRx BioPharma to Present at Investor Summit Groups Q2 Virtual Investor Summit (May 17) GlobeNewswire
07:00AM	AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit Newsfile
May-10-21 07:00AM	CEO Presenting on the Emerging Growth Conference on May 12. Register here GlobeNewswire -5.11%
Apr-15-21 07:30AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Apr-13-21 08:30AM	AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis GlobeNewswire -6.01%
Apr-06-21 09:41AM	AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections Benzinga
07:00AM	AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections GlobeNewswire
Apr-01-21 06:30AM	AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study Benzinga -23.88%
Mar-31-21 04:35PM	AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call GlobeNewswire
04:01PM	AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Mar-22-21 07:00AM	AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
Mar-16-21 07:00AM	AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire +9.09%
Mar-10-21 07:00AM	AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18) GlobeNewswire
Mar-08-21 08:00AM	AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire
07:00AM	AzurRx BioPharma to Participate in the 33rd Annual Roth Conference GlobeNewswire
Mar-02-21 07:00AM	AzurRx BioPharma to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -7.33%
Feb-24-21 07:00AM	AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors GlobeNewswire +14.19%
Feb-16-21 07:00AM	AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference GlobeNewswire
Feb-09-21 06:30AM	AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections GlobeNewswire +7.69%
Feb-08-21 08:00AM	AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference GlobeNewswire +9.74%
Jan-28-21 07:00AM	AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819 GlobeNewswire -8.54%
Jan-26-21 07:00AM	AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients GlobeNewswire -8.29%
Jan-22-21 10:18AM	AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study Zacks +48.39%
Jan-21-21 10:34AM	2 Strong Buy Penny Stocks That Could See Outsized Gains TipRanks +34.55%
08:00AM	AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients GlobeNewswire
Jan-12-21 08:30AM	AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections GlobeNewswire
Jan-08-21 09:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Jan-07-21 08:00AM	AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference GlobeNewswire
Jan-06-21 08:00AM	AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Jan-05-21 08:00AM	AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event GlobeNewswire -5.56%
Jan-04-21 07:00AM	AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections GlobeNewswire -7.22%
07:00AM	AzurRx BioPharma Announces $8.0 Million Offerings GlobeNewswire
Nov-30-20 08:00AM	AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
Nov-24-20 08:17AM	InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein GlobeNewswire
Nov-17-20 08:00AM	AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients GlobeNewswire
Nov-10-20 08:00AM	AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production GlobeNewswire
Oct-29-20 12:05PM	AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives GlobeNewswire -5.05%
Oct-21-20 08:00AM	AzurRx BioPharma Announces Formation of Scientific Advisory Board GlobeNewswire
Oct-14-20 08:00AM	AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Oct-07-20 08:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Sep-15-20 08:00AM	AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire +6.94%
Aug-31-20 06:12PM	LD Micro: 360 Companies - Set to Present this Week ACCESSWIRE
08:00AM	AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4) GlobeNewswire
Aug-26-20 06:42AM	AZRX: 1H:21 Readout for OPTION 2 and Combo Trials Zacks Small Cap Research -5.66%
Aug-17-20 08:00AM	AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Aug-13-20 08:00AM	AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire -12.39%
Aug-12-20 03:43PM	AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders GlobeNewswire +9.88%
12:20PM	AZRX: MS1819 Update: Interim Data Zacks Small Cap Research
07:29AM	The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private Benzinga
Aug-11-20 04:01PM	AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire +7.97%
Aug-05-20 11:04AM	LD Micro Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Jul-27-20 05:22AM	AZRX: Capital Raise, OPTION 2 Trial Underway Zacks Small Cap Research
Jul-22-20 08:20AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AzurRx BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire +9.52%
08:00AM	AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis with First Patient Screened and Three Clinical Trial Sites Activated GlobeNewswire
Jul-21-20 08:00AM	Alexander Capital, L.P. Congratulates AzurRx BioPharma on $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange GlobeNewswire +8.25%
Jul-20-20 08:00AM	AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange GlobeNewswire
Jun-01-20 05:45AM	AZRX: Next Up: OPTION 2 Zacks Small Cap Research
May-29-20 03:08PM	Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX) Insider Monkey
May-07-20 08:00AM	AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product GlobeNewswire
May-05-20 08:00AM	AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit) GlobeNewswire
May-04-20 06:45AM	What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)? Simply Wall St. +8.30%
Apr-30-20 08:00AM	AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Apr-29-20 08:00AM	AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites GlobeNewswire
Apr-21-20 08:00AM	AzurRx BioPharma Issues Letter to Shareholders GlobeNewswire -9.16%
Apr-20-20 08:00AM	Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX) GlobeNewswire
Apr-16-20 02:00PM	AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product GlobeNewswire +17.24%
Apr-15-20 08:00AM	AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 ACCESSWIRE -6.45%
Apr-09-20 10:30AM	AzurRx Appoints Gregory Oakes to its Board of Directors GlobeNewswire +8.93%
06:50AM	AZRX: Tax Credits Augment Cash Flow Zacks Small Cap Research
Apr-01-20 12:00PM	AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit) GlobeNewswire
Mar-18-20 08:00AM	AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th ACCESSWIRE
Mar-02-20 08:00AM	AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit) GlobeNewswire -5.08%
Feb-18-20 08:00AM	AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference GlobeNewswire
Feb-03-20 10:10AM	AZRX: EPI Treatment in the News Zacks Small Cap Research +9.99%
Jan-13-20 08:00AM	AzurRx BioPharma Announces Closing of $6.9 Million Private Placement GlobeNewswire
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO Benzinga
Jan-09-20 07:22PM	AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco GlobeNewswire +18.33%
Jan-06-20 08:00AM	AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th) GlobeNewswire
Jan-03-20 08:00AM	AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer GlobeNewswire
Nov-26-19 11:35AM	AZRX: 3Q:19 Review Zacks Small Cap Research -5.07%
Nov-14-19 08:00AM	AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC GlobeNewswire +26.98%
Oct-22-19 08:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Oct-17-19 12:30PM	AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data GlobeNewswire +24.71%
Oct-15-19 07:30AM	AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire +23.36%
Oct-10-19 07:30AM	AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer GlobeNewswire -9.94%
Sep-27-19 08:30AM	AZRX: OPTION Trial Readout Zacks Small Cap Research -11.06%
Sep-25-19 08:57AM	AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency Benzinga -21.00%
07:30AM	AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients GlobeNewswire
Aug-28-19 01:15PM	What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock? Simply Wall St.

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience